Citeline Report – Executing Early Phase Research In Hematological Oncology: What Matters To Biotech?
To view the gated content, please fill out the form below.
Significant pressure to achieve regulatory approval to start generating return on investment can affect any sponsor, but it is of the greatest importance to small biopharma companies without existing marketed products. Biopharma companies may have conducted successful research and put in the work to warrant approval and market access, but to an uninitiated sponsor bridging […]
Current Trends in the Clinical Development of Combination Therapies with Immune Checkpoint Inhibitors
In the last decade, the use of cancer immunotherapy with immune checkpoint inhibitors (ICIs) as monotherapy was defined by durable responses in numerous indications and paved the way for novel therapeutic strategies to improve treatment outcomes. Allucent identified the clinical development trends in this field that clearly favour ICIs being assessed primarily as part of […]
Immunotherapy has revolutionized cancer treatment by using a patient’s own immune system to target and eradicate tumor cells. Therapeutic tumor vaccines, as one avenue in this emerging area, are designed to elicit antigen-specific antitumor immune responses. In this paper we provide a comprehensive summary on how our expanding knowledge of immune-oncology, genomics, and bioinformatics has […]
Journal for Clinical Studies: Combination Approaches in Immuno-Oncology Trials: New Horizons for Multiple Tumor Indications
Cancer immunotherapy has steadily been gaining momentum over the last decade, due to its proven efficacy as monotherapy in patients with various tumors, including tumors resistant to chemo- or radiotherapy. With an ever-increasing amount of clinical trials reporting significant benefits in long-term overall survival of patients with specific cancers following mono-immunotherapy, the goal has shifted […]
Journal for Clinical Studies editorial – Landscape of early-phase oncology studies in the Netherlands
On the cover of Journal for Clinical Studies SMS-oncology illustrates the landscape of early-phase oncology studies in the Netherlands The Netherlands has been a natural favourite for conducting clinical research, with the Dutch healthcare system ranking among the best in Europe, the high level of education of investigators, large number of key opinion leaders, high […]
Typical Phase 1 oncology studies have changed and evolved as new techniques have developed, and target therapies have begun to reach the market. By looking at the types of drugs used, the dose levels tested and the patient populations focused on, it is possible to see where the current emphasis lies, and where unmet needs […]